Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Completed · Phase 3

Conditions studied: Hypertension

In brief

To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension

Key facts

Study ID

NCT00219180

Run by

Novartis

People needed

1797

Starts

2005-06-01

Expected to finish

2006-09-01

Last updated by the study team

2017-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with essential hypertension
• Patients who are eligible and able to participate in the study

You may not qualify if…

• Severe hypertension
• History or evidence of a secondary form of hypertension
• History of Hypertensive encephalopathy or cerebrovascular accident
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Study site — Investigative Centers, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.